

(19) **DANMARK**



Patent- og
Varemærkestyrelsen

(10) **DK/EP 3080302 T3**

(12) **Oversættelse af
europæisk patentskrift**

-
- (51) Int.Cl.: **C 12 Q 1/6874 (2018.01)** **C 12 Q 1/6881 (2018.01)**
- (45) Oversættelsen bekendtgjort den: **2020-10-26**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2020-09-16**
- (86) Europæisk ansøgning nr.: **14869706.3**
- (86) Europæisk indleveringsdag: **2014-12-10**
- (87) Den europæiske ansøgnings publiceringsdag: **2016-10-19**
- (86) International ansøgning nr.: **AU2014001114**
- (87) Internationalt publikationsnr.: **WO2015085350**
- (30) Prioritet: **2013-12-10 AU 2013904801**
- (84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (73) Patenthaver: **Conexio Genomics Pty Ltd, 36 Windsor Road, East Fremantle, Western Australia 6158, Australien**
- (72) Opfinder: **SAYER, David, Charles, 7 Windsor Road, East Fremantle, Western Australia 6158, Australien**
DESANTIS, Dianne, 20 Anzac Road, Mt Hawthorn, Western Australia 6016, Australien
- (74) Fuldmægtig i Danmark: **Novagraaf Brevets, Bâtiment O2, 2 rue Sarah Bernhardt CS90017, F-92665 Asnières-sur-Seine cedex, Frankrig**
- (54) Benævnelse: **METODER OG SONDER TIL IDENTIFIKATION AF GENALLELER**
- (56) Fremdragne publikationer:
EP-A2- 0 892 069
WO-A1-97/23645
WO-A1-99/07883
WO-A1-2009/061734
WO-A1-2010/151416
WO-A1-2012/171990
WO-A2-97/20197
WO-A2-2005/108624
WO-A2-2014/116729
US-A1- 2004 197 775
DATABASE Geneseq [Online] 11 June 2007 (2007-06-11), "Human HLA-A intron 1 genomic DNA from allele A*3002.", XP002770312, retrieved from EBI accession no. GSN:AAV46064 Database accession no. AAV46064
DATABASE EMBL [Online] 16 November 2000 (2000-11-16), "Sequence 332 from Patent WO0061795.", XP002770313, retrieved from EBI accession no. EM_PAT:AX038575 Database accession no. AX038575
DATABASE Geneseq [Online] 11 June 2007 (2007-06-11), "Histocompatibility locus antigen A intron 3 SEQ ID NO:138.", XP002770314, retrieved from EBI accession no. GSN:AAX37982 Database accession no. AAX37982
DATABASE EMBL [Online] 16 January 2001 (2001-01-16), "RC3-CI0162-201100-022-f06 CI0162 Homo sapiens

Fortsættes ...

cDNA, mRNA sequence.", XP002770315, retrieved from EBI accession no. EM_EST:BF812144 Database accession no. BF812144

DATABASE EMBL [Online] 8 July 1993 (1993-07-08), "Human MHC class I HLA-A gene, partial intron 3 (HLA-A3).", XP002770316, retrieved from EBI accession no. EM_STD:L15370 Database accession no. L15370

DATABASE EMBL [Online] 8 July 1993 (1993-07-08), "Human MHC class I HLA-A gene, partial intron 3 (HLA-A1).", XP002770317, retrieved from EBI accession no. EM_STD:L15368 Database accession no. L15368

LIND, C. ET AL.: 'Complete genomic sequencing of HLA-C*04:09n using next- generation sequencing technology' HUMAN IMMUNOLOGY vol. 71, no. SUPPL., September 2010, page S129, XP027281341

DE SANTIS, D. ET AL.: '16 (th) IHIW : review of CHLA typing by NGS' INTERNATIONAL JOURNAL OF IMMUNOGENETICS vol. 40, no. 1, February 2013, pages 72 - 76, XP055349624

GABRIEL C ET AL: "Rapid high-throughput human leukocyte antigen typing by massively parallel pyrosequencing for high-resolution allele identification", HUMAN IMMUNOLOGY, NEW YORK, NY, US, vol. 70, no. 11, 1 November 2009 (2009-11-01), pages 960-964, XP026698160, ISSN: 0198-8859, DOI: 10.1016/J.HUMIMM.2009.08.009 [retrieved on 2009-08-23]

DESCRIPTION

FIELD

[0001] The present invention relates to a method of genotyping highly polymorphic nucleic acid. In particular, the present disclosure relates to methods for genotyping highly polymorphic HLA gene alleles using high-throughput sequencing technology.

BACKGROUND

[0002] The so called next generation sequencing (NGS) technology has accelerated genetic research and enabled previously undiagnosed genetic defects to be rapidly characterized, resulting in early disease diagnosis and improved health outcomes. A key feature of next generation sequencing technology is the ability to sequence millions of single DNA molecules at the same time. The parallelism and speed of sequencing is such that it is now possible to sequence an entire human genome in just a few days. In addition to being able to sequence entire complex genomes by NGS many applications are also focusing on the clinical potential of NGS and the detection of genetic variants in specific, targeted regions.

[0003] One method of targeted genetic sequencing involves the use of labelled probes that bind to target regions which can then be extracted from genomic DNA.

[0004] The probes used can be RNA or DNA in nature and are usually in the order of 100 nucleotides in length.

[0005] The utilization of capture probes is useful for genetic regions, which in healthy individuals, tend not to be very polymorphic. That is, the genetic sequence differences between healthy individuals are in the order of <1%. A high redundancy of over lapping probes are used to ensure that if there are sequence differences between the probes and the target DNA that prevent the probe from annealing to the target sequence there will be other probes adjacent to the genetic differences that enable the extraction and sequencing of the variant DNA fragments.

[0006] Whilst the use of capture probes has wide applications, their use is not universal and considered inappropriate for the genotyping of highly polymorphic genes, like the genes of the HLA system. HLA is central to our immune response to pathogens. HLA molecules reside on the surface of cells and present fragmented pathogen peptides to the immune system. Most individuals have unique HLA types enabling the species to be able to defend against practically any pathogenic attack.

[0007] Whilst the advantages of HLA polymorphism to our species is obvious, the flipside is

that HLA antigens on transplanted organs, including hematopoietic stem cells (HSC), are seen by the recipient's immune system as "foreign" resulting in organ rejection. In the case of HSC transplants, the transplanted stem cells target the new host resulting in graft versus host disease (GvHD), a potentially fatal consequence of HSC transplants.

[0008] Therefore, genotyping of HLA is required to ensure compatibility between donors of HSC and patients. There are several HLA genes, all of which reside within approximately 4 million bases in a region known as the Major Histocompatibility Complex (MHC) located on the short arm of chromosome 6 in humans. The genes can be divided into 2 sets. The Class I genes which include HLA-A, HLA-B and HLA-C, and the class 2 genes that include HLA-DRB1, HLA-DQB1 and HLA-DPB1. It is these genes that are usually typed for transplantation purposes, but the MHC also contains additional class I HLA genes that are not very polymorphic and have functions other than pathogen derived peptide presentation. These genes include HLA-E, -F and -G. Furthermore there are numerous class I and class 2 like pseudogenes and gene fragments.

[0009] The classical class I genes are similar in sequence. They are all relatively small genes of approximately 3,200 base pairs characterized by 7-8 exons and small introns. The class 2 genes have larger introns, and some are in the order of 20,000 base pairs.

[0010] The high level of HLA polymorphism is generated by the "sharing" of sequence motifs from alleles of the same and different loci. There are relatively few unique polymorphisms and SNPs. In other words, newly identified alleles will contain a unique combination of motifs that are seen in other alleles of the same locus or from alleles of other, related, loci. Motif sharing is an effective mechanism for the rapid evolution of polymorphism and serves the species well when encountering pathogens. The size of the motif shared between alleles and loci varies. In some cases the motif may be less than 20 bp, but other alleles may contain half the entire gene. The consequence of the high level of polymorphism is that in some cases it is impossible to identify HLA matched HSC donors.

[0011] NGS for HLA offers significant benefits over conventional Sanger based sequencing techniques. Conventional HLA sequencing techniques require the sequencing of DNA amplified by polymerase chain reaction. The amplified DNA is sequenced as a plurality of sequence molecules where it cannot be determined if adjacent nucleotides are from the same or different (maternal or paternal) chromosomes. This inability to phase sequence frequently results in an inaccurate typing and a subsequent experiment is required to resolve the ambiguous type.

[0012] NGS produces single molecule sequence data, complete with phase information that can be compiled with sequence analysis software, such as Assign MPS to potentially produce an unambiguous HLA type. However, when sequencing PCR products, PCR incorporated errors and chimeric molecules are also sequenced, creating sequence analysis difficulties.

[0013] However, conventional exon based probe capture techniques are likely to be unreliable as HLA types are largely generated by motif shuffling and the degree of sequence difference

can be substantial from one allele to the next.

[0014] Thus, there remains a need for a method that enables high-throughput sequencing of highly polymorphic genes, such as the HLA genes.

[0015] WO 2010/151416 describes consensus sequences of introns from HLA-A, HLA-B, and HLA-C allotypes used to develop primers for use as sequencing primers to determine the HLA alleles in sequence-based HLA typing.

[0016] US 2004/0197775 describes a method for detection of at least one allele of a genetic locus which can be used to provide direct determination of the haplotype. The method comprises amplifying genomic DNA with a primer pair that spans an intron sequence and defines a DNA sequence in genetic linkage with an allele to be detected.

[0017] Gabriel C. et al., Rapid high-throughput human leukocyte antigen typing by massively parallel pyrosequencing for high-resolution allele identification. Human Immunology 70(11) 960-964. DOI: 10.1016/J.HUMIMM.2009.08.009, describes a HLA sequence-based typing method using the Roche/454 Life Sciences Genome Sequencer FLX system.

SUMMARY

[0018] The present inventors describe a capture probe method that is suitable for identifying alleles in highly polymorphic HLA genes by targeting capture probes to non-coding sequences. The non-coding regions of commonly typed HLA class I and class II molecules are less polymorphic than the polymorphic exons and the number of possible alternative sequences in different HLA types would appear to be relatively finite except for random SNPs that would occur through the normal process of variant generation. Thus, a small number of probes can be designed at single region that will enable the capture of all alleles, including those likely to be described in the future. The capture probes will capture DNA fragments that include the polymorphic exons and the sequencing of the capture DNA fragment will produce sequence of the polymorphic fragments enabling the deduction of an HLA type.

[0019] Accordingly, the invention provides a method for identifying one or more HLA gene alleles in a subject, the method comprising:

1. a) contacting a nucleic acid sample from the subject with oligonucleotide probes, wherein the oligonucleotide probes hybridize to HLA gene target sequences in the nucleic acid sample;
2. b) enriching for a nucleic acid that is hybridized to an oligonucleotide probe by separating it from nucleic acid not bound to an oligonucleotide probe; and
3. c) sequencing the enriched nucleic acid by high-throughput screening to identify one or more HLA gene alleles;

wherein the gene target sequences are in a non-coding region of one or more HLA genes, and wherein the oligonucleotide probes are suitable for preparing the nucleic acid for high-throughput screening using target capture.

[0020] The skilled person will understand that in preparing captured nucleic acid for sequencing, it may be desirable to amplify the captured nucleic acid. Accordingly, in one embodiment, the method comprises amplifying the nucleic bound to the oligonucleotide probe.

[0021] In one embodiment, the method comprises sequencing an HLA gene exon.

[0022] In another embodiment, the method comprises sequencing an entire HLA gene.

[0023] To facilitate enrichment of a nucleic acid of interest, in one embodiment the oligonucleotide probes comprise a capture tag.

[0024] In one embodiment, the capture tag is a hybridization tag.

[0025] In another embodiment, the capture tag is biotin or streptavidin.

[0026] In yet another embodiment, the method comprises contacting the capture tag with a binding agent.

[0027] In one embodiment, the binding agent is biotin or streptavidin.

[0028] In yet another embodiment, the binding agent is coupled to a substrate. In one particular embodiment, the binding agent is coupled to a magnetic substrate, such as for example a magnetic bead.

[0029] In one embodiment, the nucleic acid sample contacted with the oligonucleotide probes comprises single stranded nucleic acid.

[0030] In yet another embodiment, the nucleic acid sample is fragmented prior to being contacted with the oligonucleotide probes.

[0031] In one embodiment, the method comprises contacting nucleic acid fragments having an average length greater than about 100 bp with the oligonucleotide probes.

[0032] In another embodiment, the method comprises contacting nucleic acid fragments having an average length greater than about 2 kb with the oligonucleotide probes.

[0033] Alternatively, the nucleic acid sample is fragmented after it has been contacted with the oligonucleotide probes.

[0034] The oligonucleotide probes target non-coding regions of HLA genes, such as, for

example, introns and intergenic regions. In one embodiment, the non-coding region of the HLA gene is an intron.

[0035] In another embodiment, the method further comprises detecting one or more alleles of a non-HLA gene.

[0036] In the method of the present invention, the sequencing is high-throughput sequencing.

[0037] In one embodiment, the high-throughput sequencing is a next-generation sequencing technique.

[0038] In a further embodiment, the present invention provides a method for identifying HLA gene alleles in a subject, the method comprising:

1. a) fragmenting the nucleic acid sample obtained from a subject to obtain nucleic acid fragments of at least about 2 kb in length;
2. b) contacting the single-stranded nucleic acid with oligonucleotide probes comprising a capture tag, wherein the oligonucleotide probes hybridize to HLA target sequences in the nucleic acid sample;
3. c) enriching for a nucleic acid that is hybridized to an oligonucleotide probe by contacting the capture tag with a binding agent; and
4. d) sequencing the nucleic acid by high-throughput sequencing to identify one or more HLA gene alleles;

wherein the HLA target sequences are in a non-coding region of one or more HLA genes, and wherein the oligonucleotide probes are suitable for preparing the nucleic acid for high-throughput screening using target capture.

[0039] While the nucleic acid used in the method of the invention may be from a pre-obtained sample, in one embodiment, the method comprises isolating nucleic acid from a biological sample obtained from the subject.

[0040] In one embodiment, the nucleic acid sample is fragmented before being contacted with the oligonucleotide probes.

[0041] In another embodiment, the nucleic acid sample is fragmented after being contacted with the oligonucleotide probes.

[0042] In one embodiment of the first or second aspect, one or more of the oligonucleotide probes comprises a nucleic acid sequence at least 95% identical to any one of SEQ ID Nos:1-8 or 10-71.

[0043] In another embodiment, one or more of the oligonucleotide probes comprises a nucleic acid sequence at least 98% identical to any one of SEQ ID Nos:1-8 or 10-71.

[0044] In one particular embodiment, one or more of the oligonucleotide probes comprises a nucleic acid sequence identical to any one of SEQ ID Nos:1-8 or 10-71.

[0045] In a third aspect, the present invention provides a method of identifying a transplant donor for a recipient in need of a transplant, the method comprising:

1. a) performing the method of the invention to identify one or more HLA gene alleles in the recipient in need of a transplant; and
2. b) identifying a transplant donor based on the presence of one or more alleles in an HLA gene of both the transplant donor and the transplant recipient.

[0046] The present invention further provides a method of reducing the likelihood of a transplant recipient developing graft versus host disease, the method comprising:

1. a) performing the method of the invention to identify one or more HLA gene alleles in the recipient in need of a transplant; and
2. b) identifying a transplant donor based on the presence of one or more HLA gene alleles in both the transplant donor and the transplant recipient;

wherein the presence of the one or more HLA gene alleles in both the transplant recipient and the transplant donor is indicative of a reduced likelihood of the transplant recipient developing graft versus host disease following transplantation of a graft from the transplant donor.

[0047] As will be apparent, preferred features and characteristics of one aspect of the invention are applicable to many other aspects of the invention.

[0048] Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

[0049] The invention is hereinafter described by way of the following non-limiting Examples and with reference to the accompanying figures.

BRIEF DESCRIPTION OF THE FIGURES

[0050]

Figure 1. Sequence alignment of HLA-A intron 1 demonstrating that different HLA alleles have identical and predictable HLA sequence. HLA allele nomenclature utilizes up to 4 fields separated by a colon (eg A*01:01:01:01). The first field represents, in general amino acid sequence differences that can be detected by antibodies. The second field represents

nucleotide differences that result in amino acid changes but which may not be detectable with the use of antibodies. The third field represent synonymous changes and the forth field represents changes in non-coding regions. The use of letter code suffixes, such as the N in A*01:01:01:02N, indicates that the allele is an expression variant. For example N = Null or not expressed. As can be seen all A*01 alleles have identical sequence, except for 2 (A*01:02 and A*01:20) that share a nucleotide with A*30 alleles, and A*03 and A*11 alleles are also identical to the majority of A*01 alleles. Given that a probe will equally capture DNA that have a single base pair mismatch, a single probe should capture all A*01, A03, A*11 and A*30 alleles.

Figure 2. The use of Capture probes to low polymorphic non-coding regions to capture and sequence polymorphic coding regions.

Figure 3. HLA-A gene structure, showing the exons and location of the capture probes in the proof of principle experiments

Figure 4. Analysis of sequence data generated using a targeted capture sequencing protocol (colors not shown).

1. 1: Shows the gene structure for HLA above a white to red shaded region that summarizes the sequence depth across the gene. White regions indicate sequence read depths of <50 and the closer the shading to red, the less sequence read depths. Blocks of black indicate no sequence files spanning this region.
2. 2: This shows the sample name (Sample 01) and the locus being analysed (HLA-A = gA)
3. 3: This region summarises the data. Each grey vertical bar represents the amount of sequence at that position. The maximum coverage shown by this scale is 100. The horizontal line of coloured boxes is the consensus sequence where red = T, black = G, blue = C and green = A. The coloured boxes underneath represent other sequences seen at that position and where they lie on the vertical grey bar indicates the percentage of reads with that base at that position. These sequences usually represent base call errors but can indicate heterozygous sequence. The black horizontal lines indicate the percentage of base calls, so a blue box on the first horizontal line indicates that 1% of base calls at that position are C. The scale is logarithmic so that the second horizontal line indicates 10% of reads,
4. 4: This region within the software interface indicates the best matched genotype between the consensus sequence and the HLA-A library. The first 2 columns indicate the genotypes. The 3rd column indicates the number of sequence mismatches with the coding sequences of HLA-A. The next column indicates the number of mismatches with the, non-coding sequences of HLA-A and the 5th and 6th columns indicate sequence mismatches when the sequence data is phased. The correct genotype will have 0 mismatches in columns 3 to 6. In this case the best matched genotype is with HLA-A*02:01:01:01+A*02:01:01:01.

Figure 5. Results of Next generation Sequencing following Capture Probe enrichment of 3 samples also sequenced by Sanger.

KEY TO THE SEQUENCE LISTING**[0051]**

SEQ ID NOs:1 to 8 - Oligonucleotide capture probes

SEQ ID NO:9 - HLA A Intron 1

SEQ ID NOs:10 to 71 - HLA capture probe sequences

DETAILED DESCRIPTION**General Techniques and Definitions**

[0052] Unless specifically defined otherwise, all technical and scientific terms used herein shall be taken to have the same meaning as commonly understood by one of ordinary skill in the art (e.g., in molecular genetics, biochemistry, and immunology).

[0053] Unless otherwise indicated, the molecular genetics, biochemistry, and immunological techniques utilized in the present invention are standard procedures, well known to those skilled in the art. Such techniques are described and explained throughout the literature in sources such as, J. Perbal, A Practical Guide to Molecular Cloning, John Wiley and Sons (1984), J. Sambrook and Russell., Molecular Cloning: A Laboratory Manual, 3rd edn, Cold Spring Harbour Laboratory Press (2001), R. Scopes, Protein Purification - Principles and Practice, 3rd edn, Springer (1994), T.A. Brown (editor), Essential Molecular Biology: A Practical Approach, Volumes 1 and 2, IRL Press (1991), D.M. Glover and B.D. Hames (editors), DNA Cloning: A Practical Approach, Volumes 1-4, IRL Press (1995 and 1996), and F.M. Ausubel et al. (editors), Current Protocols in Molecular Biology, Greene Pub. Associates and Wiley-Interscience (1988, including all updates until present), Ed Harlow and David Lane (editors) Antibodies: A Laboratory Manual, Cold Spring Harbour Laboratory, (1988), and J.E. Coligan et al. (editors) Current Protocols in Immunology, John Wiley & Sons (including all updates until present).

[0054] The term "nucleic acid" or "nucleic acid sequence" or "nucleic acid molecule" refers to deoxyribonucleotides or ribonucleotides and polymers thereof in either single- or double-stranded form. The term nucleic acid is used interchangeably with gene, complementary DNA (cDNA), messenger RNA (mRNA), oligonucleotide, and polynucleotide.

[0055] By "isolated nucleic acid molecule" we mean a nucleic acid molecule which has generally been separated from the nucleotide sequences with which it is associated or linked in its native state (if it exists at all in nature). Preferably, the isolated nucleic acid is at least 60% free, more preferably at least 75% free, and more preferably at least 90% free from other components with which it is normally associated. The nucleic acid may be isolated from a biological sample using any suitable known technique. For example, total genomic DNA may be extracted from cells using methods known in the art and/or commercially available kits, e.g., by using the QIAamp DNA blood Mini Kit or the DNeasy Blood & Tissue Kit supplied by QIAGEN, or by using methods such as phenol/chloroform extraction and ethanol precipitation.

[0056] As used herein, the term "about", unless stated to the contrary, refers to +/-20%, more preferably +/-10%, or more preferably about +/-5% of the designated value.

Method for Identifying HLA Gene Alleles

[0057] The present inventors have now developed a method of identifying HLA gene alleles that is particularly suited to targeted capture and high-throughput sequencing techniques. The method of the invention comprises contacting a nucleic acid sample from a subject with oligonucleotide probes in order to separate genomic regions of interest from the DNA sample. Whereas prior art methods of targeted capture have relied on oligonucleotides that capture coding regions of genes of interest, these methods are not suited to genotyping highly polymorphic genes due to the difficulty in designing exon-based capture probes that are able to identify all currently described alleles as well as identify new alleles. In contrast, the present invention utilizes oligonucleotide capture probes that hybridize to HLA gene target sequences that are located in non-coding regions, thus enabling high-throughput sequencing of highly polymorphic HLA gene alleles.

[0058] Figure 1 shows a sequence alignment of HLA-A intron 1 demonstrating that different HLA alleles have identical and predictable HLA intron sequence. As can be seen, all A*01 alleles have identical sequence, except for 2 (A*01:02 and A*01:20) that share a nucleotide with A*30 alleles, and A*03 and A*11 alleles are also identical to the majority of A*01 alleles. Given that a probe will equally capture DNA that have a single base pair mismatch, a single probe should capture all A*01, A*03, A*11 and A*30 alleles.

[0059] A diagram of showing the location in captured DNA fragments of sequence that is complementary to the capture probe, as well as its relative position to the polymorphic exon is provided in Figure 2. Figure 3 demonstrates how capture probes are designed and located in order to capture the polymorphic exons for sequencing.

[0060] As used herein, the terms "non-coding sequence" or "non-coding region" refer to nucleic acid sequences that are not part of the protein coding sequence of the gene in which

alleles are identified. Thus, the terms include reference to introns, 5' and 3' un-translated regions, promoters, transcriptional regulatory elements and/or intergenic DNA. Thus, the non-coding region may be either internal to the gene of interest, or external to the gene of interest, for example, in an intergenic region. In one embodiment, the oligonucleotide probes hybridize to gene target sequences in introns in the gene of interest.

Preparation of nucleic acid

[0061] The method of the invention may be performed on a nucleic acid sample that has already been obtained from a subject using any suitable technique known in the art. Alternatively, in one embodiment, the method comprises obtaining a nucleic acid sample from a biological sample that has been obtained from the subject. As used herein, a "biological sample" may be for instance lymphocytes, whole blood, buccal swab, biopsy sample or frozen tissue or any other sample comprising genomic DNA. Although almost any tissue source can be used for molecular genotyping, lymphocytes from peripheral blood, for example, are most often used. It is also possible to utilize samples obtained through non-invasive means, for example by way of cheek swab or saliva-based DNA collection. Various suitable methods for extracting DNA from such sources are known in the art. These range from organic solvent extraction to absorption onto silica coated beads and anion exchange columns. Automated systems for DNA extraction are also available commercially and may provide good quality, high purity DNA.

[0062] The nucleic acid used in the method of the invention may be single-stranded and/or double-stranded genomic DNA. In some embodiments, the nucleic acid may include long nucleic acids comprising a length of at least about 1 kb, at least about 2 kb, at least about 5 kb, at least about 10 kb, or at least about 20 kb or longer. Long nucleic acids can be prepared from sources by a variety of methods well known in the art. Methods for obtaining biological samples and subsequent nucleic acid isolation from such samples that maintain the integrity (i.e., minimize the breakage or shearing) of nucleic acid molecules are preferred. Exemplary methods include, but are not limited to, lysis methods without further purification (e.g., chemical or enzymatic lysis method using detergents, organic solvents, alkaline, and/or proteases), nuclei isolation with or without further nucleic acid purification, isolation methods using precipitation steps, nucleic acid isolation methods using solid matrices (e.g., silica-based membranes, beads, or modified surfaces that bind nucleic acid molecules), gel-like matrices (e.g., agarose) or viscous solutions, and methods that enrich nucleic acid molecules with a density gradient.

[0063] In one embodiment, the nucleic acids used in the method of the invention are fragmented in order to obtain a desired average fragment size. The skilled person will appreciate that the required length of nucleic acid fragment will depend on the sequencing technology that is used. For example, the Ion Torrent and MisSeq platforms utilise fragments from around 100 bp - 200 bp in length, whereas the Pacific Biosciences NGS platform can utilise nucleic acid fragments up to 20 kb in length. The nucleic acid may be fragmented by

physical shearing, sonication, restriction digestion, or other suitable technique known in the art. The fragmenting of the nucleic acid can be performed so as to generate nucleic acid fragments having a desired average length. For example, the length, or the average length, of the nucleic acid fragments may be at least about 100 bp, at least about 200 bp, at least about 300 bp, at least about 400 bp, at least about 500 bp, at least about 600 bp, at least about 700 bp, at least about 800 bp, at least about 900 bp, at least about 1 kb, at least about 2 kb, at least about 3 kb, at least about 4 kb, at least about 5 kb, at least about 6 kb, at least about 7 kb, at least about 8 kb, at least about 9 kb, at least about 10 kb, at least about 11 kb, at least about 12 kb, at least about 15 kb, or at least about 20 kb.

[0064] In one embodiment, the nucleic acid sample is treated in order to generate single-stranded nucleic acid, or to generate nucleic acid comprising a single-stranded region, prior to contacting the sample with oligonucleotide probes. The nucleic acid can be made single-stranded using techniques known in the art, for example, including known hybridization techniques and commercial available kits such as the ReadyAmp™ Genomic DNA Purification System (Promega). Alternatively, single-stranded regions may be introduced into a nucleic acid using a suitable nickase in conjunction with an exonuclease.

Oligonucleotide probes

[0065] The term "probe" or "oligonucleotide probe" according to the present invention refers to an oligonucleotide which is designed to specifically hybridize to a nucleic acid of interest. Preferably, the probes are suitable for use in preparing nucleic acid for high-throughput (next-gen) sequencing using a target capture technique. Thus, in one embodiment, the probe may be suitable for target capture and be around 60 to 120 nucleotides in length. Alternatively, the probe may be about 10 to 25 nucleotides. In certain embodiments, the length of the probe is 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides. The oligonucleotide probes as used in the present invention may be ribonucleotides, deoxyribonucleotides and modified nucleotides such as inosine or nucleotides containing modified groups which do not essentially alter their hybridization characteristics.

[0066] Alternatively, the oligonucleotide probes may comprise nucleotide analogs. The term "nucleotide analogs" refers to synthetic analogs having modified nucleotide base portions, modified pentose portions, and/or modified phosphate portions, and, in the case of polynucleotides, modified internucleotide linkages, as generally described elsewhere (e.g., Scheit, Nucleotide Analogs, John Wiley, New York, (1980); Agarwal, Protocols for Polynucleotides and Analogs, Humana Press, (1994)). Generally, modified phosphate portions comprise analogs of phosphate wherein the phosphorous atom is in the +5 oxidation state and one or more of the oxygen atoms is replaced with a non-oxygen moiety, e.g., sulfur. Exemplary phosphate analogs include but are not limited to phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phosphoranilidate, phosphoramidate, boronophosphates, including associated counterions, e.g., H⁺, NH₄⁺, Na⁺, if

such counterions are present. Exemplary modified nucleotide base portions include but are not limited to 5-methylcytosine (5mC); C-5-propynyl analogs, including but not limited to, C-5 propynyl-C and C-5 propynyl-U; 2,6-diaminopurine, also known as 2-amino adenine or 2-amino-dA); hypoxanthine, pseudouridine, 2-thiopyrimidine, isocytosine (isoC), 5-methyl isoC, and isoguanine (isoG; see, e.g., U.S. Pat. No. 5,432,272). Exemplary modified pentose portions include but are not limited to, locked nucleic acid (LNA) analogs including without limitation Bz-A-LNA, 5-Me-Bz-C-LNA, dmf-G-LNA, and T-LNA, and 2'- or 3'-modifications where the 2'- or 3'-position is hydrogen, hydroxy, alkoxy (e.g., methoxy, ethoxy, allyloxy, isopropoxy, butoxy, isobutoxy and phenoxy), azido, amino, alkylamino, fluoro, chloro, or bromo. Modified internucleotide linkages include phosphate analogs, analogs having achiral and uncharged intersubunit linkages, and uncharged morpholino-based polymers having achiral intersubunit linkages (see, e.g., U.S. Pat. No. 5,034,506). Some internucleotide linkage analogs include morpholidate, acetal, and polyamide-linked heterocycles. In one class of nucleotide analogs, known as peptide nucleic acids, including pseudocomplementary peptide nucleic acids ("PNA"), a conventional sugar and internucleotide linkage has been replaced with a 2-aminoethylglycine amide backbone polymer.

Hybridization

[0067] As used herein, the term "hybridization" refers to the process in which an oligonucleotide probe binds non-covalently with a target nucleic acid to form a stable double-stranded polynucleotide. Hybridization conditions will typically include salt concentrations of less than about 1 M, more usually less than about 500 mM and may be less than about 200 mM. A hybridization buffer includes a buffered salt solution such as 5% SSPE, or other such buffers known in the art. Hybridization temperatures can be as low as 5° C, but are typically greater than 22° C, and more typically greater than about 30° C, and typically in excess of 37° C. Hybridizations are usually performed under stringent conditions, i.e., conditions under which a probe will hybridize to its target sequence to which it is complementary, but will not hybridize to the other, non-complementary sequences.

[0068] As used herein the term "complementary" and grammatical equivalents refer to the nucleotide base-pairing interaction of one nucleic acid with another nucleic acid, including modified nucleic acids and nucleic acid analogues, that results in the formation of a duplex, triplex, or other higher-ordered structure. The primary interaction is typically nucleotide base specific, e.g., A:T, A:U, and G:C, by Watson-Crick and Hoogsteen-type hydrogen bonding. Conditions under which oligonucleotide probes anneal to complementary or substantially complementary regions of target nucleic acids well known in the art

[0069] As understood in the art., stringent hybridization conditions are sequence-dependent and are different in different circumstances. For example, longer fragments may require higher hybridization temperatures for specific hybridization than short fragments. As other factors may affect the stringency of hybridization, including base composition and length of the complementary strands, presence of organic solvents, and the extent of base mismatching, the

combination of parameters is more important than the absolute measure of any one parameter alone. Generally stringent conditions are selected to be about 5° C lower than the T_m for the specific sequence at a defined ionic strength and pH. Example stringent conditions include a salt concentration of at least 0.01 M to no more than 1 M sodium ion concentration (or other salt) at a pH of about 7.0 to about 8.3 and a temperature of at least 25° C. For example, conditions of 5 × SSPE (750 mM NaCl, 50 mM sodium phosphate, 5 mM EDTA at pH 7.4) and a temperature of 30° C are suitable for allele-specific probe hybridizations.

Capture tags and binding agents

[0070] In one embodiment, the oligonucleotide probes used in the method of the present invention comprise a capture tag to facilitate enrichment of a nucleic acid of interest bound to an oligonucleotide probe from other nucleic acid sequences in a sample. In order to enrich for the nucleic acid of interest from other nucleic acid sequences, the capture tag binds to a suitable binding agent. As would be understood in the art, the phrase "enriching for a nucleic acid" refers to increasing the amount of a target nucleic acid sequence in a sample relative to nucleic acid that is not bound to an oligonucleotide probe. Thereby, the ratio of target sequence relative to the corresponding non-target nucleic acid in a sample is increased.

[0071] In one embodiment, the capture tag is a "hybridization tag". As used herein, the term "hybridization tag" and grammatical equivalents can refer to a nucleic acid comprising a sequence complementary to at least a portion of a another nucleic acid sequence that acts as the binding agent (i.e., a "binding tag"). The degree of complementarity between a hybridization tag and a corresponding binding sequence can vary with the application. In some embodiments, the hybridization tag can be complementary or substantially complementary to a binding tag or portions thereof. For example, a hybridization tag can comprise a sequence having a complementarity to a corresponding binding tag of at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, and at least about 99%. In some embodiments, a hybridization tag can comprise a sequence having 100 % complementarity to a corresponding binding tag.

[0072] In some embodiments, a capture probe can include a plurality of hybridization tags for which the corresponding binding tags are located in the same nucleic acid, or different nucleic acids. In certain embodiments, hybridization tags comprising RNA may be advantageous to efficiently remove excess levels of such tags.

[0073] In certain embodiments, a hybridization tag can comprise at least about 5 nucleotides, at least about 10 nucleotides, at least about 15 nucleotides, at least about 20 nucleotides, at least about 25 nucleotides, at least about 30 nucleotides, at least about 35 nucleotides, at least about 40 nucleotides, at least about 45 nucleotides, at least about 50 nucleotides, at least about 55 nucleotides, at least about 60 nucleotides, at least about 65 nucleotides, at least about 70 nucleotides, at least about 75 nucleotides, at least about 80 nucleotides, at least about 85 nucleotides, at least about 90 nucleotides, at least about 95 nucleotides, and at least

about 100 nucleotides,

[0074] In another embodiment, the capture tag may comprise an "affinity tag". As used herein, the term "affinity tag" and grammatical equivalents can refer to a component of a multi-component complex, wherein the components of the multi-component complex specifically interact with or bind to each other. For example an affinity tag can include biotin that can bind streptavidin. Other examples of multiple-component affinity tag complexes include, ligands and their receptors, for example, avidin-biotin, streptavidin-biotin, and derivatives of biotin, streptavidin, or avidin, including, but not limited to, 2-iminobiotin, desthiobiotin, NeutrAvidin (Molecular Probes, Eugene, Oreg.), CaptAvidin (Molecular Probes), and the like; binding proteins/peptides, including maltose-maltose binding protein (MBP), calcium-calcium binding protein/peptide (CBP); antigen-antibody, including epitope tags, including e-MYC, HA, and FLAG Tag™, and their corresponding anti-epitope antibodies; haptens, for example, dinitrophenyl and digoxigenin, and their corresponding antibodies; aptamers and their corresponding targets; fluorophores and anti-fluorophore antibodies; and the like. In one embodiment, affinity tags are used for the bulk separation of target nucleic acids comprising hybridization tags.

[0075] Thus, the binding agent used in the method of the invention is capable of binding an affinity tag as described herein to facilitate separation of a nucleic acid of interest from other nucleic acid sequences in a sample. For example, in one embodiment, the affinity tag comprises biotin and the binding agent comprises streptavidin. The binding agent is typically on a substrate. Examples of substrates include beads, microspheres, planar surfaces, columns, wells and the like. The terms "microsphere" or "bead" or "particle" or grammatical equivalents are understood in the art and refer to a small discrete particle. The composition of the substrate will vary on the application. Suitable compositions include those used in peptide, nucleic acid and organic moiety synthesis, including, but not limited to, plastics, ceramics, glass, polystyrene, methylstyrene, acrylic polymers, paramagnetic materials, thoria sol, carbon graphite, titanium dioxide, latex or cross-linked dextrans such as Sepharose, cellulose, nylon, cross-linked micelles and Teflon may all be used "Microsphere Detection Guide" from Bangs Laboratories, Fishers Ind. is a helpful guide. The beads need not be spherical; irregular particles may be used. In some embodiments, a substrate can comprise a metallic composition, e.g., ferrous, and may also comprise magnetic properties. An example embodiment utilizing magnetic beads includes capture probes comprising streptavidin-coated magnetic beads. In addition, the beads may be porous, thus increasing the surface area of the bead available for association with capture probes. The bead sizes range from nanometers, i.e. 100 nm, to millimeters, i.e. 1 mm, with beads from about 0.2 μm to about 200 μm , or from about 0.5 to about 5 μm , although in some embodiments smaller beads may be used.

High-throughput sequencing

[0076] The methods of the invention are particularly suited to preparing nucleic acid for

sequencing using a high-throughput sequencing technology such as Next-generation sequencing technology. Next-generation sequencing (NGS) technologies include instruments that are capable of sequencing more than 10^{14} kilobase-pairs (kbp) of DNA per instrument run. Sequencing typically produces a large number of independent reads, each representing anywhere between 10 to 1000 bases of the nucleic acid. Nucleic acids are generally sequenced redundantly for confidence, with replicates per unit area being referred to as the coverage (i.e., "10 × coverage" or "100 × coverage"). Next generation sequencing methods are known in the art, and are described, for example, in Metzker (2010).

[0077] Thus, the terms "Next-generation sequencing" or "NGS" or "NG sequencing" as used herein refer to any sequencing method that determines the nucleotide sequence of either individual nucleic acid molecules (e.g., in single molecule sequencing) or clonally expanded proxies for individual nucleic acid molecules in a high through-put fashion (e.g., greater than 10^3 , 10^4 , 10^5 or more molecules are sequenced simultaneously).

[0078] Platforms for next-generation sequencing include, but are not limited to, Roche/454's Genome Sequencer (GS) FLX System, Illumina/Solexa's Genome Analyzer (GA), Life/APG's Support Oligonucleotide Ligation Detection (SOLiD) system, Polonator's G.007 system, Helicos BioSciences' HeliScope Gene Sequencing system, and Pacific Biosciences' PacBio RS system.

Highly Polymorphic Genes and HLA Typing

[0079] As used herein, the term "highly polymorphic gene" includes reference to genes that have greater levels of polymorphism in the coding region of the gene compared to the non-coding regions. For example, a highly polymorphic gene may have a greater number of polymorphisms per kb of coding sequence when compared to the number of polymorphisms per kb of non-coding sequence of the gene. Well known examples of highly polymorphic genes are the human leukocyte antigen (HLA) genes.

[0080] The coding regions of HLA molecules are highly polymorphic as it is thought they are under positive select pressure to evolve in response to pathogenic threat. The non-coding regions of HLA are not under such selective pressure and do not share the same degree of polymorphism. While the non-coding regions of HLA class I are polymorphic, the polymorphisms are not randomly distributed across these regions and closely related, by coding sequence similarity, have identical non coding sequences.

[0081] Analysis of sequence alignments from non-coding regions of class I HLA reveal a limited set of unique sequences. The present inventors have determined that it is possible to design probes to each of the set of unique sequences to capture DNA fragments that can then be used in Next Gen sequencing assays.

[0082] Therefore, instead of an approach that utilizes overlapping probes from an exome (i.e.

probes designed in exon regions) the present inventors describe the use of probes designed explicitly to the non-coding regions of HLA. Figure 1 shows a sequence alignment of HLA-A intron 1 demonstrating that different HLA alleles have identical and predictable HLA sequence. HLA allele nomenclature utilizes up to four fields separated by a colon (eg A*01:01:01:01). The first field represents, in general a amino acid sequence differences that can be detected by antibodies. The second field represents nucleotide differences that result in amino acid changes but may not be detectable with the use of antibodies. The third field represent synonymous changes and the forth field represents changes in non-coding regions. The use of letter code suffixes, such as the N in A*01:01:01:02N, indicates that the allele is an expression variant. For example N = Null or not expressed. As can be seen all A*01 alleles have identical sequence, except for 2 (A*01:02 and A*01:20) that share a nucleotide with A*30 alleles, and A*03 and A*11 alleles are also identical to the majority of A*01 alleles. Given that a probe will equally capture DNA that have a single base pair mismatch, a single probe should capture all A*01, A03, A*11 and A*30 alleles.

[0083] In one embodiment, the methods of the present invention comprise identifying alleles in one or more HLA-A, HLA-B, HLA-C, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, and/or HLA-DRB1 genes.

[0084] In some embodiments, the methods of the invention are useful in determining suitable donors for transplant recipients, and/or for determining the likelihood of development of graft versus host disease (GVHD) or acute GVHD (aGVHD) in a patient by matching gene alleles, for example HLA gene alleles, in both the transplant donor and recipient.

[0085] In addition, determination of a likelihood of developing aGVHD in a transplant candidate may influence the determination as to whether transplantation is indeed the most suitable form of treatment for their condition. In some instances, there may be alternate forms of therapy available which would provide a better prognosis to the patient. Also, prediction of a likelihood of aGVHD would be indicative of the necessity for treatment regimes, or possibly more aggressive treatment regimes than would otherwise be recommended. Such aggressive therapies often have undesirable side effects and so preferably are not used unless prognosis indicates a need. For example, treatment of patients with neutralizing anti-TNF-alpha monoclonal antibodies can result in amelioration of aGVHD, but can increase risk of infections. Various aggressive anti-inflammatory therapies are also available.

[0086] As used herein, the terms "transplant" or "transplanting" refer to the grafting or introduction of tissue or cells obtained from one individual (the donor) into or onto the body of another individual (the recipient). The cells or tissue that are removed from the donor and transplanted into the recipient are referred to as a "graft". Examples of tissues commonly transplanted are bone marrow, hematopoietic stem cells, organs such as liver, heart, skin, bladder, lung, kidney, cornea, pancreas, pancreatic islets, brain tissue, bone, and intestine. The person skilled in the art would understand that the term "haplotype" refers to a combination of alleles that are located closely, or at adjacent loci, on a chromosome and that

are inherited together, or a set of single nucleotide polymorphisms on a single chromosome of a chromosome pair that are statistically associated.

Kits

[0087] Also described herein is a kit for identifying HLA gene alleles according to the method of the invention. The kit contains oligonucleotide probes that are able to hybridize to HLA gene target sequences in a non-coding region of the gene. The oligonucleotide probes may comprise a capture tag such as, for example, biotin or streptavidin. The kits may further comprise a binding agent capable of binding the capture tag. The binding agent may be coated on or attached to a suitable substrate such as, for example, a microsphere or bead. The substrate may be magnetic to facilitate enrichment of a target nucleic acid of interest.

EXAMPLES

Example 1. DNA Library Preparation

[0088] Illumina libraries were prepared from 200ng genomic DNA using the Illumina TruSeq DNA Nano protocol, selecting for target inserts of 550bp in size.

Example. 2. HLA Capture Using Intron-Specific Probes

[0089] As proof of concept, a custom oligonucleotide probe pool (SEQ ID NOs:1 to 8) targeted to intron sequences was diluted to a concentration of 1.5pmol/μl. For a first hybridization procedure, Human Cot DNA, amplified library (prepared as above), universal blocking oligo TS-p7(6nt), and universal blocking oligo TS-p7(8nt) were added to a tube and dried down in a vacuum concentrator set at 60° C for approximately 1 hour. Dried down sample was then re-suspended in Nimblegen 2X Hybridisation buffer, Nimblegen Hybridisation Component A and nuclease free water. Resuspended sample was then vortexed and denatured at 95°C for 10 minutes. Following denaturation, 2μl of probe (3pmol) was added to the sample and incubated at 72°C for 4 hours.

[0090] To wash and recover probe-hybridized DNA, wash solutions from the Nimblegen wash kits were diluted according to the manufacturers protocol. The hybridized sample was combined with streptavidin beads, vortexed and incubated at 72°C for 45 minutes. After incubation, bound DNA was washed with wash I and stringent wash at 72°C, followed by wash II and III at room temperature. The hybridised sample bound to the streptavidin beads was then placed on a magnet and the bound DNA was eluted off using 0.125N NaOH. The hybridised sample was then purified using Ampure XP beads and then amplified for 12 cycles

with KAPA HiFi HotStart ReadyMix. The primers used in the PCR were complementary to the Illumina adaptor and barcode sequences in the ligated DNA (Illumina P5 and P7). The sample was purified with Ampure XP beads.

Example 3. Sequencing of Hybridized DNA

[0091] The amplified hybridized sample was sequenced on a MiSeq or HiSeq using Illumina 2x300bp sequencing protocol.

Example 4. Results

[0092] The sequence data generated was analysed with Assign MPS v 1.0 sequence analysis software (Conexio Genomics, Fremantle, Australia). Analysis of sequence data generated using a targeted capture sequencing protocol is shown in Figure 4. Using the Assign MPS v 1.0 software, the best matched genotype for the sample was determined to be HLA-A *02:01:01:01+A*02:01:01:01.

Example 5. Next Generation Sequencing Following Capture Probe Enrichment of 3 Samples also Sequenced by Sanger

[0093] The Sanger assay amplifies HLA-A, -B and -C sequence in amplicons that span the 5' untranslated region to the end of intron 4 for HLA-A and -B and the 5' untranslated region to the 3' untranslated of HLA-C. All heterozygous ambiguities had been resolved using allele specific sequencing primers.

[0094] The Capture Probe assay was performed using the probes described in Figure 3 and provided as SEQ ID NOs:10-71, and with the protocol described in the text above. For the 3 samples there was complete concordance for the reported genotypes. The results of the assay are shown in Figure 5.

[0095] Sample 1 HLA-B contains an allele for which a reference sequence has not been reported. This allele has a single mismatch at base 444 of compared with the sequence of B*15:01:01:01, located in intron 1. By locus specific amplification using Sanger, this sample requires an additional experiment using B*08:01:01 and B*15:01:01 allele specific sequencing primers to determine if the new allele is an undescribed B*08-01:01 allele or B*15:01:01:01 allele. NGS enables phasing of polymorphisms throughout the gene and can readily identify that the new allele is a B*15:01:01 subtype. This sample also contains a novel C*04:01:01 allele. The polymorphism is located in intron 5. The use of allele specific *sequencing* primers are not commonly used in this region and characterisation by Sanger sequencing would

require the alleles to be separated by PCR, followed by Sanger sequencing. However, NGS correctly identified the new allele to be a C*04:01:01 subtype.

[0096] This data demonstrates that the use of Capture Probes enable the identification of new alleles and also the ability of NGS to determine the phase relationship of sequence polymorphisms, thus enabling the precise characterisation of the new allele.

REFERENCES

[0097] Metzker (2010) Nat Rev Genet, 11(1):31-46

SEQUENCE LISTING

[0098]

<110> Conexio Genomics Pty Ltd

<120> Methods and Probes for Identifying Gene Alleles

<130> P95258.PCT

<150> AU 2013904801

<151> 2013-12-10

<160> 71

<170> PatentIn version 3.5

<210> 1

<211> 74

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide Capture Probe 01-I1.1 (01 = allele group; I1 = intron number 1; .1 = probe one for intron)

<400> 1

cgcctctgcg gggagaagca aggggccctc ctggcggggg cgcaggaccg ggggagccgc 60

gccgggagga gggt 74

<210> 2

<211> 74

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide capture probe 01-I2.1 (01 = allele group; I2 = intron number 2; .1 = probe one for intron)

<400> 2

cacagtctcc ggggtccgaga tccaccccga agccgcggga ctccgagacc cttgtcccgg	60
gagaggccca ggcg	74

<210> 3

<211> 87

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide capture probe 01-I3.1 (01 = allele group; I3 = intron number 3; .1 = probe one for intron)

<400> 3

gtaccagggg ccacggggcg cctccctgat cgcctataga tctcccgggc tggcctccca	60
caaggagggg agacaattgg gaccaac	87

<210> 4

<211> 82

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide capture probe 01-I3.2 (01 = allele group; I3 = intron number 3; .2 = probe two for intron)

<400> 4

tatcaccctc cctctgggtcc tgagggagag gaatcctcct gggtttccag atcctgtacc	60
agagagtgac tctgaggttc cg	82

<210> 5

<211> 80

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide capture probe 01-I3.3 (01 = allele group; I3 = intron number 3; .3 = probe three for intron)

<400> 5

acacaattaa gggataaaat ctctgaagga gtgacgggaa gacgatccct cgaataactga	60
tgagtgggttc cctttgacac	80

<210> 6

<211> 86

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide capture probe 01-I3.4 (01 = allele group; I3 = intron number 3; .4 = probe four for intron)

<400> 6

ttggggcccggt gactttttcct ctcaggcctt gttctctgct tcacactcaa tgtgtgtggg 60

ggtctgagtc cagcacttct gagtct 86

<210> 7

<211> 90

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide capture probe 01-I4.1 (01 = allele group; I4 = intron number 4; .1 = probe one for intron)

<400> 7

atgggggtgt catgtctctt agggaaagca ggagcctctc tggagacctt tagcagggtc 60

aggggccctc accttccct cttttccag 90

<210> 8

<211> 79

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide capture probe 01-I5.1 (01 = allele group; I5 = intron number 5; .1 = probe one for intron)

<400> 8

cttcacaat catggggcga cccagcctgg gccctgtgtg ccagcactta ctcttttgta 60

aagcacctgt taaaatgaa 79

<210> 9

<211> 130

<212> DNA

<213> Homo sapiens

<400> 9

gtgagtgcgg ggtcgggagg gaaaccgcct ctgcggggag aagcaagggg ccctcctggc 60

gggggcgcag gaccggggga gccgcgccgg gaggagggtc gggcaggtct cagccactgc 120

tcgccccag 130

<210> 10
 <211> 127
 <212> DNA
 <213> Artificial

<220>

<223> A-3-1.1 HLA-A 3' untranslated region capture probe sequence

<400> 10
 gacagctgcc ttgtgtggga ctgagaggca agagttgttc ctgcccttcc ctttgtgact 60
 tgaagaacct tgactttgtt tctgcaaagg cacctgcatg tgtctgtgtt cgtgtaggca 120
 taatgtg 127

<210> 11
 <211> 120
 <212> DNA
 <213> Artificial Sequence

<220>

<223> A-5-1.1 HLA-A 5' untranslated region capture probe sequence

<400> 11
 cagggcgaag tcccagggcc ccaggcgtgg ctctcagggt ctcaggcccc gaaggcgggtg 60
 tatggattgg ggagtcccag ccttggggat tccccaaactc cgcagtttct tttctccctc 120

<210> 12
 <211> 120
 <212> DNA
 <213> Artificial Sequence

<220>

<223> A-5-2.1 HLA-A 5' untranslated region capture probe sequence

<400> 12
 cctggatact cacgacgcgg acccagttct cactcccatt ggggtgctggg tttccagaga 60
 agccaatcag tgtcgtcgcg gtcgctgttc taaagcccgc acgcaccac cgggactcag 120

<210> 13
 <211> 112
 <212> DNA
 <213> Artificial Sequence

<220>

<223> A-I1-1.1 HLA-A Intron 1 capture probe sequence

<400> 13
 gggaaacggc ctctgcgggg agaagcaagg ggcccgcgcc gcggggggcgc aggacccggg 60

aagccgcgcc gggaggaggg tcgggcgggt ctcagccact cctcgcccc ag 112

<210> 14

<211> 112

<212> DNA

<213> Artificial Sequence

<220>

<223> A-I1-1-2 HLA-A Intron 1 capture probe sequence

<400> 14

gggaaaccgc ctctgcgggg agaagcaagg ggccctcctg gcgggggcgc aggaccgggg 60

gagccgcgcc gggaggaggg tcgggcaggt ctcagccact gctcgcccc ag 112

<210> 15

<211> 115

<212> DNA

<213> Artificial Sequence

<220>

<223> A-I2-1.1 HLA-A Intron 2 capture probe sequence

<400> 15

gcaggtcacg accctcatc ccccacggac gggccaggtc gccacagtc tccgggtccg 60

agatccaccc cgaagccgcg ggggtccgag acccttgctc cgggagaggc ccagg 115

<210> 16

<211> 111

<212> DNA

<213> Artificial Sequence

<220>

<223> A-I2-2.1 HLA-A Intron 2 capture probe sequence

<400> 16

gaggcccagg cgcctttaac ccggtttcat tttcagttta ggccaaaaat cccccgggt 60

tggtcggggc ggggcggggc tcgggggacc gggctgacct cggggtccgg g 111

<210> 17

<211> 110

<212> DNA

<213> Artificial Sequence

<220>

<223> A-I2-2.2 HLA-A Intron 2 capture probe sequence

<400> 17

gaggcccagg cgcctttacc ccggtttcatt ttcagtttag gccaaaaatc cccccgggtt 60

ggtcggggcc gggcggggct cgggggactg ggctgaccgc ggggtcgggg 110

<210> 18
<211> 113
<212> DNA
<213> Artificial Sequence

<220>
<223> A-I3-1.1 HLA-A Intron 3 capture probe sequence

<400> 18
gatcgctgt agatctccg ggctggcctc ccacaagaaa gggagacaaa tgggaccaac 60
actataatat cgcctccct ctggtcttga gggagaagaa tcctcctggg ttt 113

<210> 19
<211> 113
<212> DNA
<213> Artificial Sequence

<220>
<223> A-I3-1.2 HLA-A Intron 3 capture probe sequence

<400> 19
gatcgctgt agatctccg ggctggcctc ccacaaggag gggagacaat tgggaccaac 60
actagaatat cgcctccct ctggtcctga gggagaggaa tcctcctggg ttt 113

<210> 20
<211> 103
<212> DNA
<213> Artificial Sequence

<220>
<223> A-I3-2.1 HLA-A Intron 3 capture probe sequence

<400> 20
ctgggttctg tgctctcttc cccatcccgg gtgtcctgtc cattctcaag atggccacat 60
gcgtgctggg ggagtgtccc atgacagatg caaaatgcct gaa 103

<210> 21
<211> 103
<212> DNA
<213> Artificial Sequence

<220>
<223> A-I3-2.2 HLA-A Intron 3 capture probe sequence

<400> 21
ctgggttctg tgctctcttc cccatcccag gtgtcctgtc cattctcaag atagccacat 60
gtgtgctgga ggagtgtccc atgacagatg caaaatgcct gaa 103

<210> 22
<211> 100
<212> DNA
<213> Artificial Sequence

<220>
<223> A-I3-2.3 HLA-A Intron 3 capture probe sequence

<400> 22
ctggggttctg tgctctcttc cccatcccgg gtgtcctgtc cattctcaag atggccacat 60
gcatgctgga gtgtcccatg acagatgcaa aatgcctgaa 100

<210> 23
<211> 103
<212> DNA
<213> Artificial Sequence

<220>
<223> A-I3-2.4 HLA-A Intron 3 capture probe sequence

<400> 23
ctggggttctg tgctctcttc cccatcccag gtgtcctgtc catcctcaaa atggccacat 60
gcgtgctggg ggagtgtccc atgacagatg caaaatggct gaa 103

<210> 24
<211> 101
<212> DNA
<213> Artificial Sequence

<220>
<223> A-I4-1.1 HLA-A Intron 4 capture probe sequence

<400> 24
taaggagggg gatgggggtg tcatgtctct tagggaaagc aggagcctct ctggagacct 60
ttagcagggg cagggccctt caccttcccc tcttttccca g 101

<210> 25
<211> 98
<212> DNA
<213> Artificial Sequence

<220>
<223> A-I4-1.2 HLA-A Intron 4 capture probe sequence

<400> 25
taaggagggg gacgggggtg tcatgtcttt tagggaaagc aggagcctct ctgaccttta 60
gcagggtcag ggccccctac cttccccctct tttcccag 98

<210> 26
<211> 96
<212> DNA
<213> Artificial Sequence

<220>
<223> A-I4-1.3 HLA-A Intron 4 capture probe sequence

<400> 26
taaggaggga gatgggggtg tcatgtcttt tacggaaagc aggagcctct ctgaccttta 60
gcagggtcag ggccctcac ctcccccttt tcccag 96

<210> 27
<211> 113
<212> DNA
<213> Artificial Sequence

<220>
<223> A-I5-1.1 HLA-A Intron 5 capture probe sequence

<400> 27
tctgagattt cttgtctcac tgagggttcc aagaccagg tagaagtgtg ccctgcctcg 60
ttactgggaa gcaccatcca caattatggg cctaccagc ctgggccctg tgt 113

<210> 28
<211> 113
<212> DNA
<213> Artificial Sequence

<220>
<223> A-I5-1.2 HLA-A Intron 5 capture probe sequence

<400> 28
tctgagattt cttgtctcac tgagggttcc aagccccagc tagaaatgtg ccctgtctca 60
ttactgggaa gcaccatcca caatcatggg cctaccagc ctgggccctg tgt 113

<210> 29
<211> 114
<212> DNA
<213> Artificial Sequence

<220>
<223> A-I5-2.1 HLA-A Intron 5 capture probe sequence

<400> 29
ccctgggtct gcagtcacac atttctggaa acttctctga ggtccaagac ttggaggttc 60
ctctaggacc ttaaggccct gactccttcc tggatatcca caggacattt tctt 114

<210> 30

<211> 114

<212> DNA

<213> Artificial Sequence

<220>

<223> A-I5-2.2 HLA-A Intron 5 capture probe sequence

<400> 30

ccctgggtct gcattcacac atttctggaa acttctctgg ggtccaaggc taagaggttc 60

ctctaggacc ttaaggccct ggctcctttc tggtagctca caggacattt tctt 114

<210> 31

<211> 120

<212> DNA

<213> Artificial Sequence

<220>

<223> B-3-1.1 HLA-B 3' untranslated region capture probe sequence

<400> 31

cagaatttgt tcatgactgt tgttttctgt agcctgagac agctgtcttg tgagggactg 60

agatgcagga tttcttcact cctccctttt gtgacttcaa gagcctctgg catctctttc 120

<210> 32

<211> 114

<212> DNA

<213> Artificial Sequence

<220>

<223> B-5-1.1 HLA-B 5' untranslated region capture probe sequence

<400> 32

gatcaggacg aagtcccagg tcccggacgg ggctctcagg gtctcaggct ccgagggccg 60

cgtctgcaat ggggaggcgc agcgttgggg attccccact cccatgagtt tcac 114

<210> 33

<211> 114

<212> DNA

<213> Artificial Sequence

<220>

<223> B-5-1.2 HLA-B 5' untranslated region capture probe sequence

<400> 33

gatcaggacg aagtcccagg ccccgggccc ggctctcagg gtctcaggct ccgagagccg 60

cgtctgcatt ggggaggcgc agcgttgggg attccccact cccacgagtt tcac 114

<210> 34

<211> 110

<212> DNA

<213> Artificial Sequence

<220>

<223> B-5-2.1 HLA-B 5' untranslated region capture probe sequence

<400> 34

ttcccactcc cattgggtgt cgggtgtcta gagaagccaa tcagtgtcgc cggggtccca 60

gttctaaagt ccccacgcac ccacccggac tcaaatctc ctcagacgcc 110

<210> 35

<211> 110

<212> DNA

<213> Artificial Sequence

<220>

<223> B-5-2.2 HLA-B 5' untranslated region capture probe sequence

<400> 35

ttcccactcc cattgggtat tggatatcta gagaagccaa tcagcgtcgc cggggtccca 60

gttctaaagt ccccacgcac ccacccggac tcagagtctc ctcagacgcc 110

<210> 36

<211> 110

<212> DNA

<213> Artificial Sequence

<220>

<223> B-5-2.3 HLA-B 5' untranslated region capture probe sequence

<400> 36

ttcccactcc cattgggtgt cggatatcta gagaagccaa tcagcgtcgc cggggtccca 60

gttctaaagt ccccacgcac ccacccggac tcagagtctc ctcagacgcc 110

<210> 37

<211> 101

<212> DNA

<213> Artificial Sequence

<220>

<223> B-I1-1.1 HLA-B Intron 1 capture probe sequence

<400> 37

gggaaatggc ctctgtgggg aggagcgagg ggaccgcagg cggggggcgca ggacccgggg 60

agccgcgccg ggaggagggt cgggccctc ctcgccccca g 101

<210> 38

<211> 108

<212> DNA
<213> Artificial Sequence

<220>
<223> B-I1-1.2 HLA-B Intron 1 capture probe sequence

<400> 38
gggaaatggc ctctgccggg aggagcgagg ggaccgcagg cggggggcgca ggacctgagg 60
agccgcgccg ggaggagggg cgggcgggtc tcagccctc ctcacccc 108

<210> 39
<211> 115
<212> DNA
<213> Artificial Sequence

<220>
<223> B-I2-1.1 HLA-B Intron 2 capture probe sequence

<400> 39
gtgagtgacc ccggcccggg gcgcaggtca cgactcccca tccccacgg acggcccggg 60
tcgccccgag tctccgggtc cgagatccgc ctccctgagg ccgcgggacc cgccc 115

<210> 40
<211> 113
<212> DNA
<213> Artificial Sequence

<220>
<223> B-I2-1.2 HLA-B Intron 2 capture probe sequence

<400> 40
gtgagtgacc ccggcccggg gcgcaggtca cgactcccca tccccacgt acggcccggg 60
tcgccccgag tctccgggtc cgagatccgc ccccgaggcc gcgggaccg ccc 113

<210> 41
<211> 115
<212> DNA
<213> Artificial Sequence

<220>
<223> B-I2-1.3 HLA-B Intron 2 capture probe sequence

<400> 41
gtgagtgacc ccggcctggg gcgcaggtca cgacccctcc ccaacccga cgtacggccc 60
gggtctcctc gagtctctag gtccgagatc cgccccgagg ccgcgggacc cgccc 115

<210> 42
<211> 110

<212> DNA
<213> Artificial Sequence

<220>
<223> B-I2-2.1 HLA-B Intron 2 capture probe sequence

<400> 42
gccgcgggac ccgcccagac cctcgaccgg cgagagcccc aggcgcgttt acccggtttc 60
attttcagtt gaggccaaaa tccccgcggg ttggtcgggg gggggcgggg 110

<210> 43
<211> 110
<212> DNA
<213> Artificial Sequence

<220>
<223> B-I2-2.2 HLA-B Intron 2 capture probe sequence

<400> 43
gccgcgggac ccgcccagaa cctcgaccgc agagagcccc aggcgaattt acccggtttc 60
attttcagtt gaggtcaaaa gccccgcggg ttggtcaggg gggggcgggg 110

<210> 44
<211> 98
<212> DNA
<213> Artificial Sequence

<220>
<223> B-I3-1.1 HLA-B Intron 3 capture probe sequence

<400> 44
gtaccagggg cagtggggag ccttcccat ctctatagg tcgccgggga tggcctccca 60
cgagaagaag aggaaaatgg gatcagcgct agaatgtc 98

<210> 45
<211> 98
<212> DNA
<213> Artificial Sequence

<220>
<223> B-I3-1.2 HLA-B Intron 3 capture probe sequence

<400> 45
gtaccagggg cagtggggag ccttcccat ctctataga tcgccgggga tggcctccca 60
cgaggagggg aggaaaatga gagaagcgct agaatgtc 98

<210> 46
<211> 126
<212> DNA

<213> Artificial Sequence

<220>

<223> B-I3-2.1 HLA-B Intron 3 capture probe sequence

<400> 46

tgtctggggtt ctgtgcccct tccccacccc aggtgtcctg tccattctca ggctggtcac	60
atgggtgggtc ctaggggtgtc ccatgaaaga tgcaaagcgc ctgaattttc tgactcttcc	120
catcag	126

<210> 47

<211> 93

<212> DNA

<213> Artificial Sequence

<220>

<223> B-I4-1.1 HLA-B Intron 4 capture probe sequence

<400> 47

gtaaggaggg ggatgagggg tcatatctct tctcagggaa agcaggagcc cttcagcagg	60
gtcagggccc ctcattcttc cctcctttcc cag	93

<210> 48

<211> 104

<212> DNA

<213> Artificial Sequence

<220>

<223> B-I4-1.2 HLA-B Intron 4 capture probe sequence

<400> 48

gtaaggaggg ggatgagggg tcatatctct tctcagggaa agcaggagcc cttctggagc	60
ccttcagcag ggtcagggcc cctcattctc cctcctttc ccag	104

<210> 49

<211> 115

<212> DNA

<213> Artificial Sequence

<220>

<223> B-I5-1.1 HLA-B Intron 5 capture probe sequence

<400> 49

gtaggggaagg ggtgaggggt ggggtctggg ttttcttgtc ccactggggg tttcaagccc	60
caggtagaag tgttccctgc ctcaattactg ggaagcagca tgcacacagg ggcta	115

<210> 50

<211> 120

<212> DNA

<213> Artificial Sequence

<220>

<223> B-I5-2.1 HLA-B Intron 5 capture probe sequence

<400> 50

ctttcctcgt gtttcctgat cctgccctgg gtctgtagtc atacttctgg aaattctttt 60

tgggtccaag actaggaggt tcctctaaga tctcatggcc ctgcttcctc ccagtcacct 120

<210> 51

<211> 115

<212> DNA

<213> Artificial Sequence

<220>

<223> C-3-2.1 HLA-C 3' untranslated region capture probe sequence

<400> 51

gacagctgcc tgtgtgggac tgagatgcag gatttcttca cacctctcct ttgtgacttc 60

aagagcctct ggcactctct tctgcaaagg catctgaatg tgtctgcggt cctgt 115

<210> 52

<211> 110

<212> DNA

<213> Artificial Sequence

<220>

<223> C-5-1.1 HLA-C 5' untranslated region capture probe sequence

<400> 52

caggacgaag tcccaggtcc cgggcggggc tctcagggtc tcaggctcca agggccgtgt 60

ctgcactggg gaggcgcgcg gttggggatt ctccactccc ctgagtttca 110

<210> 53

<211> 116

<212> DNA

<213> Artificial Sequence

<220>

<223> C-5-1.2 HLA-C 5' untranslated region capture probe sequence

<400> 53

caggacgaag tcccaggtcc cgggcggggc tctctgggtc tcaagctccc agggccgtgt 60

ctgcattggg gaggcgcagc gttggggatt cccactccc actccctga gtttca 116

<210> 54

<211> 109

<212> DNA

<213> Artificial Sequence

<220>

<223> C-5-2.1 HLA-C 5' untranslated region capture probe sequence

<400> 54

ctcatgacgc gtccccaatt cccactccca ttgggtgtcg gattctagag aagccaatca 60

gcgtctccgc agtcccgggt ctgaagtccc cagtcaccca cccggactc 109

<210> 55

<211> 102

<212> DNA

<213> Artificial Sequence

<220>

<223> C-5-2.2 HLA-C 5' untranslated region capture probe sequence

<400> 55

ctcatgacgc gtccccaatt cccactccca ttgggtgtcg ggttctagag aagccaatca 60

gcgtctacgc agtcccgggt ctgaagtcac ccacccggac tc 102

<210> 56

<211> 112

<212> DNA

<213> Artificial Sequence

<220>

<223> C-I1-1.1 HLA-C Intron 1 capture probe sequence

<400> 56

ggttgggagg gaagcggcct ctgcggagag gacgcagggg cccgcccggc gagggcgag 60

gacccgggga gccgcgcagg gaggtgggtc gggcgggtct cagccctcc tc 112

<210> 57

<211> 97

<212> DNA

<213> Artificial Sequence

<220>

<223> C-I2-1.1 HLA-C Intron 1 capture probe sequence

<400> 57

gtgagtgacc ccggcccggg gcgcaggtca cgacccctcc ccatccccca cggacggccc 60

gggtcgcccc gagtctcccg gtctgagatc caccocg 97

<210> 58

<211> 97

<212> DNA

<213> Artificial Sequence

<220>

<223> C-I2-1.2 HLA-C Intron 1 capture probe sequence

<400> 58

gtgagtgacc ccggcccggg gcgcaggtca cgacccctcc ccatccccca cggacggccc 60

gggtcgcccta gagtctcccc gtctgagatc caccoca 97

<210> 59

<211> 114

<212> DNA

<213> Artificial Sequence

<220>

<223> C-I2-2.1 HLA-C Intron 2 capture probe sequence

<400> 59

gcggaacccg ccagaccct cgaccggaga gagccccagt cacctttacc cggtttcatt 60

ttcagtttag gccaaaatcc ccgcgggttg gtcggggcgg ggcggggctc gggg 114

<210> 60

<211> 115

<212> DNA

<213> Artificial Sequence

<220>

<223> C-I2-2.2 HLA-C Intron 2 capture probe sequence

<400> 60

gcggaacccg ccagaccct cgaccggaga gagccctagt cgcctttacc cggtttcatt 60

ttcagtttag gccaaaatcc ccgcgggttg gtcggggctg ggcgggggtt cgggg 115

<210> 61

<211> 115

<212> DNA

<213> Artificial Sequence

<220>

<223> C-I2-2.3 HLA-C Intron 2 capture probe sequence

<400> 61

gcggaacccg ccagaccct cgaccggaga gagccccagt cacctttacc cggtttcatt 60

ttcagtttag gccaaaatcc ccgcgggttg gtcggggctg ggcgggggtt cgggg 115

<210> 62

<211> 108

<212> DNA

<213> Artificial Sequence

<220>

<223> C-13-1.1a HLA-C Intron 3 capture probe sequence

<400> 62

gggcagtggg gagccttccc catctcctgt agatctcccg ggatggcctc ccacgaggag 60

gggaggaaaa tgggatcagc gctagaatat cgccctccct tgaatgga 108

<210> 63

<211> 110

<212> DNA

<213> Artificial Sequence

<220>

<223> C-I3-1.1b HLA-C Intron 3 capture probe sequence

<400> 63

cccccttccc caccctcagggt gtccctgtcca ttctcaggat agtcacatgg gcgctgttgg 60

agtgtcgcaa gagagatada aagtgtctga attttctgac tcttcccgta 110

<210> 64

<211> 110

<212> DNA

<213> Artificial Sequence

<220>

<223> C-I3-1.2 HLA-C Intron 3 capture probe sequence

<400> 64

ccgccttccc caccctcagggt gtccctgtcca ttctcaggat ggtcacatgg gcgctgctgg 60

agtgtcccaa gagagatgca aagtgtctga attttctgac tcttcccgta 110

<210> 65

<211> 117

<212> DNA

<213> Artificial Sequence

<220>

<223> C-I4-1.1 HLA-C Intron 4 capture probe sequence

<400> 65

ggaggggggat gaggggtcat gtgtcttctc agggaaagca gaagtcctgg agcccttcag 60

ccgggtcagg gctgaggctt gggggtcagg gccctcacc ttccctcctt ttcccag 117

<210> 66

<211> 100

<212> DNA

<213> Artificial Sequence

<220>
<223> C-I4-1.2 HLA-C Intron 4 capture probe sequence

<400> 66
ggaggggggat gaggggtgat atctgttctc agggaaagca ggagcccttc tggagccctt 60
cagcaggggtc agggccccctc accttccccct cctttcccag 100

<210> 67
<211> 120
<212> DNA
<213> Artificial Sequence

<220>
<223> C-I4-1.3 HLA-C Intron 4 capture probe sequence

<400> 67
ggagggggaat ggggggtcac atctcttctc agagaaagca gaagtccttc tggagccctt 60
cagccgggtc agggctgagg cttgggggtc agggccccctc accttctcct cctttcccag 120

<210> 68
<211> 120
<212> DNA
<213> Artificial Sequence

<220>
<223> C-I4-1.4 HLA-C Intron 4 capture probe sequence

<400> 68
ggaggggggat gaggggtcat gtgtcttctc agggaaagca gaagtccttc tggagccctt 60
cagccgggtc agggctgagg cttgggtgta agggccccctc accttccccct cctttcccag 120

<210> 69
<211> 110
<212> DNA
<213> Artificial Sequence

<220>
<223> C-I5-1.1 HLA-C Intron 5 capture probe sequence

<400> 69
gggtctgggt tttcttgtcc cactgggagt ttcaagcccc aggtagaagt gtgccccacc 60
tcgttactgg aagcaccatc cacacctggg ccatcccagc ctgggacct 110

<210> 70
<211> 118
<212> DNA
<213> Artificial Sequence

<220>

<223> C-I5-2-1 HLA-C Intron 5 capture probe sequence

<400> 70
cctgggtctg cagtcatagt tctggaaact tctcttgggt ccaagactag gaggttcccc 60
taagatcgca tggccctgcc tctccctgt cccctcacag ggcattttct tcccacag 118

<210> 71
<211> 118
<212> DNA
<213> Artificial Sequence

<220>
<223> C-I5-2-2 HLA-C Intron 5 capture probe sequence

<400> 71
cctgggtctg cagtcgtagt tctggaaact tctcttgggt ccaagactag gaggttcccc 60
taaaatcaca tggccctgcc tctccctgt cccctcatag ggcattttct tcccacag 118

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- [WO2010151416A \[0015\]](#)
- [US20040197775A \[0016\]](#)
- [US5432272A \[0066\]](#)
- [US5034506A \[0066\]](#)
- [AU2013904801 \[0098\]](#)

Non-patent literature cited in the description

- **GABRIEL C. et al.**Rapid high-throughput human leukocyte antigen typing by massively

parallel pyrosequencing for high-resolution allele identification Human Immunology, vol. 70, 11960-964 [0017]

- **J, PERBALA** Practical Guide to Molecular Cloning John Wiley and Sons 19840000 [0053]
- **J. SAMBROOKRUSSELL** Molecular Cloning: A Laboratory Manual Cold Spring Harbour Laboratory Press 20010000 [0053]
- **R. SCOPES** Protein Purification - Principals and Practice Springer 19940000 [0053]
- **Essential Molecular Biology: A Practical Approach** IRL Press 19910000 vol. 1 and 2, [0053]
- **DNA Cloning: A Practical Approach** IRL Press 19950000 vol. 1-4, [0053]
- **Current Protocols in Molecular Biology** Greene Pub. Associates and Wiley-Interscience 19880000 [0053]
- **Antibodies: A Laboratory Manual** Cold Spring Harbour Laboratory 19880000 [0053]
- **Current Protocols in Immunology** John Wiley & Sons [0053]
- **SCHEIT** Nucleotide Analogs John Wiley 19800000 [0066]
- **AGARWAL** Protocols for Polynucleotides and Analogs Humana Press 19940000 [0066]
- **METZKERN** Nat Rev Genet, 2010, vol. 11, 131-46 [0097]

Patentkrav

1. Fremgangsmåde til identifikation af et eller flere HLA-genalleler i et emne, hvilken fremgangsmåde omfatter:

a) at sætte en nukleinsyreprøve fra emnet i forbindelse med

5 oligonukleotidsonder, hvor en eller flere af oligonukleotidsonderne hybridiserer til HLA-gen-målesekvenser i nukleinsyreprøven;

b) berigelse for en nukleinsyre, der hybridiseres til en oligonukleotidsonde ved at adskille den fra nukleinsyre, der ikke er bundet til en oligonukleotidsonde; og

10 c) sekvensering af den berigede nukleinsyre ved screening med høj kapacitet for at identificere en eller flere HLA-genalleler;

hvor gen-målesekvenserne er i et ikke-kodende område med et eller flere HLA-gener, og

hvor oligonukleotidsonderne er egnede til at forberede nukleinsyren til screening med høj kapacitet ved hjælp af målfangst (target capture).

15

2. Fremgangsmåde ifølge krav 1, hvor oligonukleotidsonderne omfatter et indfangningsmærke (capture tag).

20 **3.** Fremgangsmåde ifølge et hvilket som helst af de foregående krav, hvor nukleinsyreprøven, der er sat i forbindelse med oligonukleotidsonden, omfatter enkeltstrenget nukleinsyre.

25 **4.** Fremgangsmåde ifølge ethvert af krav 1 til 3, hvor nukleinsyreprøven er fragmenteret, inden den sættes i forbindelse med oligonukleotidsonderne.

5. Fremgangsmåde ifølge krav 1, hvilken fremgangsmåde yderligere omfatter fragmentering af nukleinsyreprøven for at opnå nukleinsyrefragmenter på mindst ca. 2 kb i længden før trin (a).

30

6. Fremgangsmåde ifølge et hvilket som helst af de foregående krav, hvor en eller flere af oligonukleotidsonderne omfatter en nukleinsyresekvens, der er mindst 95% identisk

med en hvilken som helst af SEQ ID-nr.:1-8 eller 10-71.

7. Fremgangsmåde til identifikation af en transplantationsdonor til en modtager, der har behov for en transplantation, hvilken fremgangsmåde omfatter:

- 5 a) udførelse af en fremgangsmåde ifølge et hvilket som helst af de foregående krav til identifikation af en eller flere HLA-genalleler hos den modtager, der har behov for en transplantation; og
- b) identifikation af en transplantationsdonor baseret på tilstedeværelsen af en eller flere alleler i et HLA-gen af både transplantationsdonoren og
- 10 transplantationsmodtageren.

8. Fremgangsmåde til reduktion af sandsynligheden for at en transplantationsmodtager udvikler graft-versus-host sygdom, hvilken fremgangsmåde omfatter:

- 15 a) udførelse af en fremgangsmåde ifølge et hvilket som helst af de foregående krav til identifikation af en eller flere HLA-genalleler hos den modtager, der har behov for en transplantation; og
 - b) identifikation af en transplantationsdonor baseret på tilstedeværelsen af en eller flere HLA-genalleler i både transplantationsdonoren og
 - 20 transplantationsmodtageren
- hvor tilstedeværelsen af en eller flere HLA-genalleler i både transplantationsmodtageren og transplantationsdonoren er tegn på en reduceret sandsynlighed for, at transplantationsmodtageren udvikler graft-versus-host sygdom efter transplantation af et transplantat fra transplantationsdonoren.

DRAWINGS

HLA Alleles	HLA A Intron 1 Sequence												
	30	90	100	110	120	130	140						
gDNA													
A*01:01:01:01 (SEQ ID:9)	GTGAGTG	CGGGGTCCGG	AGGGAACCG	CCTCTGCGGG	GAGAAGCAAG	GGGCCCTCCT	GGCGGGGGCG						
A*01:01:01:02N	-----	-----	-----	-----	-----	-----	-----						
A*01:01:01:38L	-----	-----	-----	-----	-----	-----	-----						
A*01:03	-----	-----	-----	-----	-----	-----	-----						
A*01:04N	-----	-----	-----	-----	-----	-----	-----						
A*01:09	-----	-----	-----	-----	-----	-----	-----						
A*01:11N	-----	-----	-----	-----	-----	-----	-----						
A*01:14	-----	-----	-----	-----	-----	-----	-----						
A*01:16N	-----	-----	-----	-----	-----	-----	-----						
A*11:01:01	-----	-----	-----	-----	-----	-----	-----						
A*11:01:18	-----	-----	-----	-----	-----	-----	-----						
A*11:02:01	-----	-----	-----	-----	-----	-----	-----						
A*11:05	-----	-----	-----	-----	-----	-----	-----						
A*11:25	-----	-----	-----	-----	-----	-----	-----						
A*11:50Q	-----	-----	-----	-----	-----	-----	-----						
A*11:60	-----	-----	-----	-----	-----	-----	-----						
A*11:69N	-----	-----	-----	-----	-----	-----	-----						
A*11:74	-----	-----	-----	-----	-----	-----	-----						
A*11:75	-----	-----	-----	-----	-----	-----	-----						
A*11:77	-----	-----	-----	-----	-----	-----	-----						
A*11:110	-----	-----	-----	-----	-----	-----	-----						
A*36:01	-----	-----	-----	-----	-----	-----	-----						
A*01:02	-----	-----	-----	-----	-----	-----	-----						

Figure 1

[illegible]

Figure 1 continued

A*02:48	-----	-----	-----	-----G-	-----T---	-----C	-----G---	-----
A*02:51	-----	-----	-----	-----G-	-----T---	-----C	-----G---	-----
A*02:53N	-----	-----	-----	-----G-	-----T---	-----C	-----G---	-----
A*02:57	-----	-----	-----	-----G-	-----T---	-----C	-----G---	-----
A*02:60:01	-----	-----	-----	-----G-	-----T---	-----C	-----G---	-----
A*02:65	-----	-----	-----	-----G-	-----T---	-----C	-----G---	-----
A*02:68	-----	-----	-----	-----G-	-----T---	-----C	-----G---	-----
A*02:77	-----	-----	-----	-----G-	-----T---	-----C	-----G---	-----
A*02:81	-----	-----	-----	-----G-	-----T---	-----C	-----G---	-----
A*02:89	-----	-----	-----	-----G-	-----T---	-----C	-----G---	-----
A*02:95	-----	-----	-----	-----G-	-----T---	-----C	-----G---	-----
A*02:251	-----	-----	-----	-----G-	-----T---	-----C	-----G---	-----
A*02:259	-----	-----	-----	-----G-	-----T---	-----C	-----G---	-----
A*02:264	-----	-----	-----	-----G-	-----T---	-----C	-----G---	-----
A*02:265	-----	-----	-----	-----G-	-----T---	-----C	-----G---	-----
A*02:266	-----	-----	-----	-----G-	-----T---	-----C	-----G---	-----
A*02:269	-----	-----	-----	-----G-	-----T---	-----C	-----G---	-----
A*02:279	-----	-----	-----	-----G-	-----T---	-----C	-----G---	-----
A*02:376	-----	-----	-----	-----G-	-----T---	-----C	-----G---	-----
A*02:455	-----	-----	-----	-----G-	-----T---	-----C	-----G---	-----
A*02:533	-----	-----	-----	-----G-	-----T---	-----C	-----G---	-----
A*23:01:01	-----	-----	-----	-----G-	-----T---	-----	-----G---	-----
A*23:09	-----	-----	-----	-----G-	-----T---	-----	-----G---	-----
A*23:38N	-----	-----	-----	-----G-	-----T---	-----	-----G---	-----
A*24:02:01:01	-----	-----	-----	-----G-	-----T---	-----	-----G---	-----
A*24:02:01:02L	-----	-----	-----	-----G-	-----T---	-----	-----G---	-----

Figure 1 continued

A*24:02:01:03	-----	-----	-----G-	-----	-----	-----G----	-----
A*24:02:03Q	-----	-----	-----G-	-----	-----	-----G----	-----
A*24:02:10	-----	-----	-----G-	-----	-----	-----G----	-----
A*24:09N	-----	-----	-----G-	-----	-----	-----G----	-----
A*24:10:01	-----	-----	-----G-	-----	-----	-----G----	-----
A*24:11N	-----	-----	-----G-	-----	-----	-----G----	-----
A*24:20	-----	-----	-----G-	-----	-----	-----G----	-----
A*24:61	-----	-----	-----G-	-----	-----	-----G----	-----
A*24:86N	-----	-----	-----G-	-----	-----	-----G----	-----
A*24:152	-----	-----	-----G-	-----	-----	-----G----	-----
A*24:215	-----	-----	-----G-	-----	-----	-----G----	-----
A*25:01:01	-----	-----	-----G-	-----T----	-----	-----G-C	-----
A*26:01:01	-----	-----	-----G-	-----T----	-----	-----G-C	-----
A*26:11N	-----	-----	-----G-	-----T----	-----	-----G-C	-----
A*26:15	-----	-----	-----G-	-----T----	-----	-----G-C	-----
A*26:50	-----	-----	-----G-	-----T----	-----	-----G-C	-----
A*29:01:01:01	-----	-----T-	-----	-----	-----	-----G-C	-----A--
A*29:01:01:02N	-----	-----T-	-----	-----	-----	-----G-C	-----A--
A*29:02:01:01	-----	-----T-	-----	-----	-----	-----G-C	-----A--
A*29:02:01:02	-----	-----T-	-----	-----	-----	-----G-C	-----A--
A*29:46	-----	-----T-	-----	-----	-----	-----G-C	-----A--
A*31:01:02	-----	-----T-	-----	-----	-----	-----G-C	-----
A*31:01:23	-----	-----T-	-----	-----	-----	-----G-C	-----
A*31:04	-----	-----T-	-----	-----	-----	-----G-C	-----
A*31:14N	-----	-----T-	-----	-----	-----	-----G-C	-----
A*31:46	-----	-----T-	-----	-----	-----	-----G-C	-----

Figure 1 continued

A*33:01:01	-----	-----T-	-----G-	-----	-----G-C	-----
A*33:03:01	-----	-----T-	-----	-----	-----G-C	-----
A*33:07	-----	-----T-	-----	-----	-----G-C	-----
A*24:03:01	-----	-----	-----G-	-----	-----G-	-----
A*24:07:01	-----	-----	-----G-	-----	-----G-	-----
A*24:08	-----	-----	-----G-	-----	-----G-	-----
A*32:01:01	-----	-----T-	-----	-----	-----G-C	-----
A*32:06	-----	-----T-	-----	-----	-----G-C	-----
A*74:01	-----	-----T-	-----	-----	-----G-C	-----
A*74:02:01:01	-----	-----T-	-----	-----	-----G-C	-----
A*74:02:01:02	-----	-----T-	-----	-----	-----G-C	-----
A*34:01:01	-----	-----	-----G-	-----T-----	-----G-C	-----
A*34:02:01	-----	-----	-----G-	-----T-----	-----G-C	-----
A*43:01	-----	-----	-----G-	-----T-----	-----G-C	-----
A*66:01:01	-----	-----	-----G-	-----T-----	-----G-C	-----
A*66:17	-----	-----	-----G-	-----T-----	-----G-C	-----
A*68:01:01:01	-----	-----	-----G-	-----T-----	-----G-C	-----
A*68:01:01:02	-----	-----	-----G-	-----T-----	-----G-C	-----
A*68:01:02:01	-----	-----	-----G-	-----T-----	-----G-C	-----
A*68:01:02:02	-----	-----	-----G-	-----T-----	-----G-C	-----
A*68:02:01:01	-----	-----	-----G-	-----T-----	-----G-C	-----
A*68:02:01:02	-----	-----	-----G-	-----T-----	-----G-C	-----
A*68:02:01:03	-----	-----	-----G-	-----T-----	-----G-C	-----
A*68:02:02	-----	-----	-----G-	-----T-----	-----G-C	-----
A*68:03:01	-----	-----	-----G-	-----T-----	-----G-C	-----
A*68:08:01	-----	-----	-----G-	-----T-----	-----G-C	-----

Figure 1 continued

[illegible]

Figure 1 continued

A*11:69N	-----	-----	-----	-----	-----	-----	-----	-----	-----
A*11:74	-----	-----	-----	-----	-----	-----	-----	-----	-----
A*11:75	-----	-----	-----	-----	-----	-----	-----	-----	-----
A*11:77	-----	-----	-----	-----	-----	-----	-----	-----	-----
A*11:110	-----	-----	-----	-----	-----	-----	-----	-----	-----
A*36:01	-----	-----	-----	-----	-----	-----	-----	-----	-----
A*01:02	-----	-----	-----	-----	-----	-----	T-----	-----	-----
A*01:20	-----	-----	-----	-----	-----	-----	T-----	-----	-----
A*03:01:01:01	-----	-----	-----	-----	-----	-----	-----	-----	-----
A*03:01:01:02N	-----	-----	-----	-----	-----	-----	-----	-----	-----
A*03:01:01:03	-----	-----	-----	-----	-----	-----	-----	-----	-----
A*03:02:01	-----	-----	-----	-----	-----	-----	-----	-----	-----
A*03:11N	-----	-----	-----	-----	-----	-----	-----	-----	-----
A*03:21N	-----	-----	-----	-----	-----	-----	-----	-----	-----
A*03:36N	-----	-----	-----	-----	-----	-----	-----	-----	-----
A*30:01:01	-----	-----	-----	-----	-----	-----	T-----	-----	-----
A*30:02:01:01	-----	-----	-----	-----	-----	-----	T-----	-----	-----
A*30:02:01:02	-----	-----	-----	-----	-----	-----	T-----	-----	-----
A*30:04:01	-----	-----	-----	-----	-----	-----	T-----	-----	-----
A*30:89	-----	-----	-----	-----	-----	-----	T-----	-----	-----
A*02:01:01:01	-----C--	-A-----	-----	-----	-----	-----	-----G--	-C---T--	-----
A*02:01:01:02L	-----C--	-A-----	-----	-----	-----	-----	-----G--	-C---T--	-----
A*02:01:01:03	--A-----C--	-A-----	-----	-----	-----	-----	-----G--	-C---T--	-----
A*02:01:01:04	-----C--	-A-----	-----	-----	-----	-----	-----G--	-C---T--	-----
A*02:02:01	-----C--	-A-----	-----	-----	-----	-----	-----G--	-C---T--	-----
A*02:03:01	-----C--	-A-----	-----	-----	-----	-----	-----G--	-C---T--	-----

Figure 1 continued

A*02:03:03	A-----C--	A-----	-----	-----G--	-----	-C---T---	---
A*02:05:01	-----C--	A-----	-----	-----G--	-----	-C---T---	---
A*02:06:01	-----C--	A-----	-----	-----G--	-----	-C---T---	---
A*02:07:01	-----C--	A-----	-----	-----G--	-----	-C---T---	---
A*02:10	-----C--	A-----	-----	-----G--	-----	-C---T---	---
A*02:32N	-----C--	A-----	-----	-----G--	-----	-C---T---	---
A*02:43N	-----C--	A-----	-----	-----G--	-----	-C---T---	---
A*02:48	-----C--	A-----	-----	-----G--	-----	-C---T---	---
A*02:51	-----C--	A-----	-----	-----G--	-----	-C---T---	---
A*02:53N	-----C--	A-----	-----	-----G--	-----	-C---T---	---
A*02:57	-----C--	A-----	-----	-----G--	-----	-C---T---	---
A*02:60:01	-----C--	A-----	-----	-----G--	-----	-C---T---	---
A*02:65	-----C--	A-----	-----	-----G--	-----	-C---T---	---
A*02:68	-----C--	A-----	-----	-----G--	-----	-C---T---	---
A*02:77	-----C--	A-----	-----	-----G--	-----	-C---T---	---
A*02:81	-----C--	A-----	-----	-----G--	-----	-C---T---	---
A*02:89	-----C--	A-----	-----	-----G--	-----	-C---T---	---
A*02:95	-----C--	A-----	-----	-----G--	-----	-C---T---	---
A*02:251	-----C--	A-----	-----	-----G--	-----	-C---T---	---
A*02:259	-----C--	A-----	-----	-----G--	-----	-C---T---	---
A*02:264	-----C--	A-----	-----	-----G--	-----	-C---T---	---
A*02:265	-----C--	A-----	-----	-----G--	-----	-C---T---	---
A*02:266	-----C--	A-----	-----	-----G--	-----	-C---T---	---
A*02:269	-----C--	A-----	-----	-----G--	-----	-C---T---	---
A*02:279	-----C--	A-----	-----	-----G--	-----	-C---T---	---
A*02:376	-----C--	A-----	-----	-----G--	-----	-C---T---	---

Figure 1 continued

A*02:455	-----C--	-A-----	-----	-----G--	-----	-C---T---	---
A*02:533	-----C--	-A-----	-----	-----G--	-----	-C---T---	---
A*23:01:01	--A---C--	-A-----	-----	-----G--	-----	-C---T---	---
A*23:09	--A---C--	-A-----	-----	-----G--	-----	-C---T---	---
A*23:38N	--A---C--	-A-----	-----	-----G--	-----	-C---T---	---
A*24:02:01:01	--A---C--	-A-----	-----	-----G--	-----	-C---T---	---
A*24:02:01:02L	--A---C--	-A-----	-----	-----G--	-----	-C---T---	---
A*24:02:01:03	--A---C--	-A-----	-----	-----G--	-----	-C---T---	---
A*24:02:03Q	--A---C--	-A-----	-----	-----G--	-----	-C---T---	---
A*24:02:10	--A---C--	-A-----	-----	-----G--	-----	-C---T---	---
A*24:03:01	--A---C--	-A-----	-----	-----G--	-----	-C---T---	---
A*24:07:01	--A---C--	-A-----	-----	-----G--	-----	-C---T---	---
A*24:08	--A---C--	-A-----	-----	-----G--	-----	-C---T---	---
A*24:09N	--A---C--	-A-----	-----	-----G--	-----	-C---T---	---
A*24:10:01	--A---C--	-A-----	-----	-----G--	-----	-C---T---	---
A*24:11N	--A---C--	-A-----	-----	-----G--	-----	-C---T---	---
A*24:20	--A---C--	-A-----	-----	-----G--	-----	-C---T---	---
A*24:61	--A---C--	-A-----	-----	-----G--	-----	-C---T---	---
A*24:86N	--A---C--	-A-----	-----	-----G--	-----	-C---T---	---
A*24:152	--A---C--	-A-----	-----	-----G--	-----	-C---T---	---
A*24:215	--A---C--	-A-----	-----	-----G--	-----	-C---T---	---
A*25:01:01	-----C--	-A-----	-T-----	-----G--	-----	-C-----	---
A*26:01:01	-----C--	-A-----	-T-----	-----G--	-----	-C-----	---
A*26:11N	-----C--	-A-----	-T-----	-----G--	-----	-C-----	---
A*26:15	-----C--	-A-----	-T-----	-----G--	-----	-C-----	---
A*26:50	-----C--	-A-----	-T-----	-----G--	-----	-C-----	---

Figure 1 continued

A*29:01:01:01	-----C--	-T-----	-----	-----TG--	-----	-C-----	---
A*29:01:01:02N	-----C--	-T-----	-----	-----TG--	-----C-----	-C-----	---
A*29:02:01:01	-----C--	-T-----	-----	-----TG--	-----	-C-----	---
A*29:02:01:02	-----C--	-T-----	-----	-----TG--	-----	-C-----	---
A*29:46	-----C--	-T-----	-----	-----TG--	-----	-C-----	---
A*31:01:02	-----C--	-T-----	-----	-----G-A	-----	-C-----	---
A*31:01:23	-----C--	-T-----	-----	-----G-A	-----	-C-----	---
A*31:04	-----C--	-T-----	-----	-----G-A	-----	-C-----	---
A*31:14N	-----C--	-T-----	-----	-----G-A	-----	-C-----	---
A*31:46	-----C--	-T-----	-----	-----G-A	-----	-C-----	---
A*33:01:01	-----C--	-T-----	-----	-----G-A	-----	-C-----	---
A*33:03:01	-----C--	-T-----	-----	-----G-A	-----	-C-----	---
A*33:07	-----C--	-T-----	-----	-----G-A	-----	-C-----	---
A*32:01:01	-----C--	-T-----	-----	-----G--	-----	-C-----	---
A*32:06	-----C--	-T-----	-----	-----G--	-----	-C-----	---
A*74:01	-----C--	-T-----	-----	-----G--	-----	-C-----	---
A*74:02:01:01	-----C--	-T-----	-----	-----G--	-----	-C-----	---
A*74:02:01:02	-----C--	-T-----	-----	-----G--	-----	-C-----	---
A*34:01:01	-----C--	-A-----	-T-----	-----G--	-----	-C-----	---
A*34:02:01	-----C--	-A-----	-T-----	-----G--	-----	-C-----	---
A*43:01	-----C--	-A-----	-T-----	-----G--	-----	-C-----	---
A*66:01:01	-----C--	-A-----	-T-----	-----G--	-----	-C-----	---
A*66:17	-----C--	-A-----	-T-----	-----G--	-----	-C-----	---
A*68:01:01:01	-----C--	-A-----	-T-----	-----G--	-----	-C-----	---
A*68:01:01:02	-----C--	-A-----	-T-----	-----G--	-----	-C-----	---
A*68:01:02:01	-----C--	-A-----	-T-----	-----G--	-----	-C-----	---

Figure 1 continued

A*68:01:02:02	-----C--	-A-----	-T-----	-----G--	-----	-C-----	---
A*68:02:01:01	-----C--	-A-----	-T-----	-----G--	-----	-C-----	---
A*68:02:01:02	-----C--	-A-----	-T-----	-----G--	-----	-C-----	---
A*68:02:01:03	-----C--	-A-----	-T-----	-----G--	-----	-C-----	---
A*68:02:02	-----C--	-A-----	-T-----	-----G--	-----	-C-----	---
A*68:03:01	-----C--	-A-----	-T-----	-----G--	-----	-C-----	---
A*68:08:01	-----C--	-A-----	-T-----	-----G--	-----	-C-----	---
A*68:17	-----C--	-A-----	-T-----	-----G--	-----	-C-----	---
A*68:18N	-----C--	-A-----	-T-----	-----G--	-----	-C-----	---
A*68:22	-----C--	-A-----	-T-----	-----G--	-----	-C-----	---
A*68:71	-----C--	-A-----	-T-----	-----G--	-----	-C-----	---
A*68:113	-----C--	-A-----	-T-----	-----G--	-----	-C-----	---
A*69:01	-----C--	-A-----	-T-----	-----G--	-----	-C-----	---
A*80:01:01:01	-----C--	-A-----	-----	-----G--	-----	-C-----	---
A*80:01:01:02	-----C--	-A-----	-----	-----G--	-----	-C-----	---

Figure 1 continued




Figure 2




Figure 3




Figure 4

Sample	Locus	Reported Genotypes	
		Sanger	Capture Probe
Sample 1	HLA A	01:01:01:01	01:01:01:01
	HLA A	24:02:01:01	24:02:01:01
	HLA B	08:01:01	08:01:01
	HLA B	15:01:01*	15:01:01*
	HLA C	04:01:01*	04:01:01*
	HLA C	07:01:01:01	07:01:01:01
Sample 2	HLA A	02:01:01:01	02:01:01:01
	HLA A	31:01:02	31:01:02
	HLA B	27:05:02	27:05:02
	HLA B	40:01:02	40:01:02
	HLA C	02:02:02:01	02:02:02:01
	HLA C	03:04:01:01	03:04:01:01
Sample 3	HLA A	03:01:01:01	03:01:01:01
	HLA A	24:03:01	24:03:01
	HLA B	39:06:02	39:06:02
	HLA B	50:01:01	50:01:01
	HLA C	12:03:01:01	12:03:01:01
	HLA C	15:04	15:04

Figure 5